Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsA lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.
An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.
1.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
2.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
3.
Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer
4.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
5.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
1.
The Digital Biopsy: How Artificial Intelligence is Redefining Cancer Pathology?
2.
MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps
3.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part VIII
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge